Curis vs TScan Therapeutics
CRIS and TCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and TCRX compare
TScan Therapeutics is the larger company, worth 12 times as much as Curis ($10.9M against $930K).
Curis scores higher on the StockData Score (5 against 4 for TScan Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | TCRX |
|---|---|---|
| Size and price | ||
| Market cap | $930K | $10.9M |
| Share price | $0.445 | $0.161 |
| Change, 1 year | −98.2% | −86.5% |
| Change, 5 years | −100.0% | −98.2% |
| Beta (5Y) | 1.90 | 0.92 |
| Employees | 24 | 142 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 2.1× |
| P/B | 0.4× | 0.3× (better) |
| FCF yield | – | −1026% |
| Fair value | – | $0.823 |
| Margin of safety | – | 80.5% |
| Growth | ||
| Revenue growth (TTM) | – | −38.4% |
| Revenue growth, 5Y average | −2.7% | 56.9% (better) |
| Profitability | ||
| Operating margin | – | −2247% |
| Net margin | – | −2219% |
| FCF margin | – | −2153% |
| Return on equity | – | −126% |
| Financial health | ||
| Debt / equity | 0.00 | 0.87 (better) |
| Interest coverage | – | −40.7× |
| Current ratio | 0.43 | 2.03 (better) |
| Altman Z-score | −98.36 | −8.20 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.1% | 53.5% |
| Held by insiders | 20.4% | 32.8% |
| Insider net buying, 12 months | $5.5K | $146K (better) |
| Short interest, % of float | 61.8% | 4.4% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- TCRX stock overview
- TCRX income statement
- TCRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.